GAMBACORTI PASSERINI, CARLO

GAMBACORTI PASSERINI, CARLO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 22 (tempo di esecuzione: 0.016 secondi).
Titolo Data di pubblicazione Autori
The ALK gene, an attractive target for inhibitor development 1-gen-2011 TARTARI, CARMEN GIULIAGAMBACORTI PASSERINI, CARLO +
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 1-gen-2011 MOLOGNI, LUCAVILTADI, MICHELAGAMBACORTI PASSERINI, CARLO +
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 1-gen-2012 MOLOGNI, LUCACECCON, MONICAGAMBACORTI PASSERINI, CARLO +
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 1-gen-2013 PIAZZA, ROCCO GIOVANNIVALLETTA, SIMONAREDAELLI, SARASPINELLI, ROBERTAPIROLA, ALESSANDRAANTOLINI, LAURAMOLOGNI, LUCADONADONI, CARLAGAIPA, GIUSEPPEDE MARTINI, GRETA PIERAMAGISTRONI, VERAPOGLIANI, ENRICO MARIAGAMBACORTI PASSERINI, CARLO +
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 1-gen-2013 MOLOGNI, LUCAREDAELLI, SARAGAMBACORTI PASSERINI, CARLO +
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 1-gen-2013 CECCON, MONICAMOLOGNI, LUCAGAMBACORTI PASSERINI, CARLO +
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 1-gen-2011 GAMBACORTI PASSERINI, CARLOPIAZZA, ROCCO GIOVANNI
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias 7-nov-2013 GAMBACORTI PASSERINI, CARLO +
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 1-gen-2014 REDAELLI, SARAPERINI, PIETROCECCON, MONICAPIAZZA, ROCCO GIOVANNIRIGOLIO, ROBERTAGAMBACORTI PASSERINI, CARLO +
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors 1-dic-2013 GAMBACORTI PASSERINI, CARLO +
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 1-gen-2013 PIAZZA, ROCCO GIOVANNIMAGISTRONI, VERAMOGAVERO, ANGELAMOLOGNI, LUCAGAMBACORTI PASSERINI, CARLO +
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 1-gen-2015 GAMBACORTI PASSERINI, CARLODONADONI, CARLAPIROLA, ALESSANDRAREDAELLI, SARAFONTANA, DILETTASPINELLI, ROBERTAMAGISTRONI, VERAPERONACI, MARCOPIAZZA, ROCCO GIOVANNI +
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia 1-gen-2014 GAMBACORTI PASSERINI, CARLO +
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 15-feb-2006 GAMBACORTI PASSERINI, CARLO +
An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase 1-lug-2005 GAMBACORTI PASSERINI, CARLO +
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 7-mar-2007 COLUCCIA, ADDOLORATAMOLOGNI, LUCAREDAELLI, SARAGAMBACORTI PASSERINI, CARLO +
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 1-gen-2005 PIAZZA, ROCCO GIOVANNIMAGISTRONI, VERAGAMBACORTI PASSERINI, CARLO +
Prognostic variables in patients with chronic myeloid leukemia treated with imatinib 1-feb-2006 GAMBACORTI PASSERINI, CARLO
Response to 'D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients' by Leguay et al 1-gen-2005 PIAZZA, ROCCO GIOVANNIMAGISTRONI, VERAGAMBACORTI PASSERINI, CARLO +
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 1-set-2007 GAMBACORTI PASSERINI, CARLO +